They were a few questions about FDA and safety but they responded that they don't expected any additional reviews to have any impact on current sales or on adding new patients, as the there is already a warning on the drug as is. The drug was approved with the benefits outweighing the risks.
After noting that patients were still coming on therapy and sales were generally rising, CEO Davis repeated key defenses from its above referenced issues statement, then he went to the crux of the matter, stating:
So while it's early and may be a little bumpy in the near-term as we work through this, we have not seen a meaningful impact on the business that will lead us to change our full year 2018 guidance of a $255 million to $270 million.
News 
Market Data 
Discover 
